Lilly’s donanemab slowed Alzheimer’s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

by admin

Lilly’s donanemab slowed Alzheimer’s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM …

Category: Dementia